339 related articles for article (PubMed ID: 23295809)
21. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
22. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
23. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
24. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
25. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
[TBL] [Abstract][Full Text] [Related]
26. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
[TBL] [Abstract][Full Text] [Related]
27. Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up.
Wiernik PH; Hong F; Glick JH; Bennett JM
Leuk Lymphoma; 2009 Oct; 50(10):1632-41. PubMed ID: 19863338
[TBL] [Abstract][Full Text] [Related]
28. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
Ezzat HM; Cheung MC; Hicks LK; Boro J; Montaner JS; Lima VD; Harris M; Leitch HA
Leuk Lymphoma; 2012 Dec; 53(12):2390-6. PubMed ID: 22642935
[TBL] [Abstract][Full Text] [Related]
29. Second cancer among long-term survivors from Hodgkin's disease.
Nyandoto P; Muhonen T; Joensuu H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):373-8. PubMed ID: 9788418
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
Gordon LI; Hong F; Fisher RI; Bartlett NL; Connors JM; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Gospodarowicz M; Advani R; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
J Clin Oncol; 2013 Feb; 31(6):684-91. PubMed ID: 23182987
[TBL] [Abstract][Full Text] [Related]
31. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
[TBL] [Abstract][Full Text] [Related]
32. [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
Kochbati L; Boussen H; Benna F; Belhaj Ali Z; Gammoudi A; Bouaouina N; Besbes M; Ghilen L; Rahal K; Maalej M
Cancer Radiother; 2003 Oct; 7(5):302-7. PubMed ID: 14522350
[TBL] [Abstract][Full Text] [Related]
33. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
34. Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
Hamilton VM; Norris C; Bunin N; Goldwein JW; Bunin GR; Lange B; Meadows AT
J Pediatr Hematol Oncol; 2001 Feb; 23(2):84-8. PubMed ID: 11216711
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy.
van den Berg H; Stuve W; Behrendt H
Med Pediatr Oncol; 1997 Jul; 29(1):23-7. PubMed ID: 9142201
[TBL] [Abstract][Full Text] [Related]
36. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
Dann EJ; Bairey O; Bar-Shalom R; Mashiach T; Barzilai E; Kornberg A; Akria L; Tadmor T; Filanovsky K; Abadi U; Kagna O; Ruchlemer R; Abdah-Bortnyak R; Goldschmidt N; Epelbaum R; Horowitz NA; Lavie D; Ben-Yehuda D; Shpilberg O; Paltiel O
Br J Haematol; 2017 Sep; 178(5):709-718. PubMed ID: 28589704
[TBL] [Abstract][Full Text] [Related]
37. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T; Bellei M; Luminari S; Montanini A; Marcheselli L; Levis A; Gobbi P; Vitolo U; Stelitano C; Pavone V; Merli F; Liberati M; Baldini L; Bordonaro R; Pesce EA; Federico M
J Clin Oncol; 2011 Nov; 29(32):4227-33. PubMed ID: 21990405
[TBL] [Abstract][Full Text] [Related]
39. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
40. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).
Wannesson L; Bargetzi M; Cairoli A; Cerutti A; Heim D; Hess U; Lerch E; Pabst T; Renner C; Samaras P; Zucca E
Leuk Lymphoma; 2013 Jan; 54(1):36-40. PubMed ID: 22702653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
